Trial: 201701042

A Phase II Open-Label,Randomized Study of PARP inhibition (olaparib) Either Alone or in Combination with Anti-PD-LI Therapy (atezolizumab;MPDL3280A) in Homologous DNA Repair (HDR) Deficient Triple Negative Breast Cancer (TNBC)

Phase

II

Principal Investigator

Park, Haeseong

Disease Site

Breast

Learn more about this study at: clinicaltrials.gov